/SLRN

SLRN Stock - Acelyrin, Inc.

Q: What is the analyst price target for SLRN?

Analyst price target information is not currently available for SLRN.

Q: What is SLRN's market cap?

Market capitalization information is not currently available for SLRN.

Healthcare|Biotechnology|NASDAQ

$2.27+0.00%

+$0.00 (+0.00%) • May 21

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+399.1%upside

Target: $11.33

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for SLRN

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.09

52W High$7.25

52W Low$1.84

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021
Revenue	N/A	N/A	N/A	N/A
Gross Profit	$-423,000	$-115,000	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A
Operating Income	$-316,258,000	$-422,064,000	$-69,179,000	$-41,794,000
Net Income	$-248,226,000	$-381,641,000	$-250,461,000	$-41,839,000
Net Margin	N/A	N/A	N/A	N/A
EPS	$-2.50	$-5.43	$-0.70	$-2.05

Company Overview

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

43%

Hold / Neutral

57%

Sell / Underperform

Analyst Consensus🔴 Bearish

3 Bullish4 Neutral/Bearish

Price Targets

$25

Average Target

↑ 1001.3% Upside

Now

Low

$25

Average

$68

High

Based on 8 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
August 14th 2024	H.C. Wainwright	Downgrade	Neutral	$6← $18
July 8th 2024	Wells Fargo	Upgrade	Overweight	$13
December 13th 2023	Wells Fargo	Initiation	Equal Weight	$11
December 8th 2023	Citigroup	Initiation	Neutral	$8
September 13th 2023	Morgan Stanley	Downgrade	Equal Weight	$19
September 5th 2023	H.C. Wainwright	Initiation	Buy	$44
May 30th 2023	Morgan Stanley	Initiation	Overweight	-
May 30th 2023	Jefferies	Initiation	Buy	$31
May 30th 2023	Piper Sandler	Initiation	Overweight	$68
May 30th 2023	TD Cowen	Initiation	Outperform	-

Earnings History & Surprises

SLRN

Beat Rate

78%

Last 9 quarters

Avg Surprise

+19.4%

EPS vs Estimate

Beats / Misses

7/2

Last 12 quarters

Latest EPS

$-0.55

Q2 2025

EPS Surprise History

Q3 23

+30.9%

$-0.56vs$-0.81

Q4 23

-85.1%

$-0.87vs$-0.47

Q1 24

+25.0%

$-0.75vs$-1.00

Q2 24

+61.3%

$-0.36vs$-0.93

Q3 24

-30.3%

$-0.86vs$-0.66

Q4 24

+41.7%

$-0.49vs$-0.84

Q1 25

+8.1%

$-0.79vs$-0.86

Q2 25

+42.1%

$-0.55vs$-0.95

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2025	Nov 11, 2025	—	—	—	—
Q3 2025	Aug 12, 2025	$-0.71	—	—	—
Q2 2025	May 14, 2025	$-0.95	$-0.55	+42.1%	✓ BEAT
Q1 2025	Mar 19, 2025	$-0.86	$-0.79	+8.1%	✓ BEAT
Q4 2024	Nov 13, 2024	$-0.84	$-0.49	+41.7%	✓ BEAT
Q3 2024	Aug 13, 2024	$-0.66	$-0.86	-30.3%	✗ MISS
Q2 2024	May 14, 2024	$-0.93	$-0.36	+61.3%	✓ BEAT
Q1 2024	Mar 28, 2024	$-1.00	$-0.75	+25.0%	✓ BEAT
Q4 2023	Nov 7, 2023	$-0.47	$-0.87	-85.1%	✗ MISS
Q3 2023	Aug 14, 2023	$-0.81	$-0.56	+30.9%	✓ BEAT
Q2 2023	Jun 15, 2023	$-10.89	$-2.11	+80.6%	✓ BEAT
Q2 2023	May 5, 2023	—	$-10.43	—	—
Q3 2022	Sep 30, 2022	—	$-0.70	—	—
Q2 2022	Jun 30, 2022	—	$-0.71	—	—
Q1 2022	Mar 31, 2022	—	$-0.79	—	—